We recently caught up with Andreas Schätzlein of the University of London. In describing his progress in developing a micelluar drug delivery technology and a dendrimer-based gene delivery vector, mention of his company Nanomerics (see the LRJ Nov 6 2006) was curiously absent. It turns out that Andr...
This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!
News Commentary | May 05, 2021
Chimeric antigen receptor T cell (CAR‑T) therapy is already clinically available, with five FDA‑approved therapies for cancers like leukemia, lymphoma, and multiple myeloma. Now, Nkarta, a clinical‑stage biotech company, is developing another version – a CAR‑natural killer (CAR‑NK) cell therapy. The... Not part of subscription
News Commentary | May 07, 2021
Multiple new and emerging COVID‑19 variants with higher transmission rates have thrown into question the continued efficacy of existing vaccines across these newer strains. Previous research has focused on the receptor‑binding domain (RBD) given its importance in attaching to and infecting human ... To read more, click here.
News Commentary | July 30, 2021
Google‑backed Calico and pharma giant AbbVie are doubling down on tackling aging‑related diseases with this second partnership extension. Twenty early‑stage programs have been developed across oncology and neurodegeneration, with the lead oncology target, which acts at multiple steps in the cancer ... Not part of subscription